Tacrolimus Eye Drops

Verify with FDA CVM →

10 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
10
Total Reports
2
Deaths Reported
2000.0%
Death Rate

Active Ingredients

Tacrolimus Eye Drops

Administration Routes

OphthalmicUnknownOther

Species Affected

Dog 10

Most Affected Breeds

Maltese 2
Shih Tzu 2
Boxer (German Boxer) 1
Poodle - Toy 1
Crossbred Canine/dog 1
Mountain Dog - Pyrenean 1
Bulldog - English 1
Cattle Dog - Australian (blue heeler, red heeler, Queensland cattledog) 1

Most Reported Reactions

Vomiting 4
Weight loss 3
Abnormal adrenocorticotropic hormone (ACTH) stimulation test 2
Not eating 2
Elevated serum alkaline phosphatase (ALP) 2
Intestinal disorder NOS 2
Eye disorder NOS (for Photophobia see neurological) 2
Seizure NOS 2
Death by euthanasia 2
Gingival hyperplasia 1
Other abnormal test result NOS 1
Elevated serum alkaline phosphatase (SAP) 1

Outcome Breakdown

Ongoing
5 (50.0%)
Outcome Unknown
3 (30.0%)
Euthanized
2 (20.0%)

Data Summary

Metric Value
Total adverse event reports 10
Reports involving death 2
Case-fatality rate (reported events) 2000.0%
Distinct species in reports 1
Distinct breeds in reports 8
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Tacrolimus Eye Drops Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 10 adverse event reports referencing Tacrolimus Eye Drops, including 2 reports in which the animal died — a 2000.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Tacrolimus Eye Drops. Reported administration routes include Ophthalmic, Unknown, Other. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Tacrolimus Eye Drops reports are Dog (10 reports), with Dog accounting for the largest share. Within those species, Maltese (2), Shih Tzu (2), Boxer (German Boxer) (1) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Tacrolimus Eye Drops are Vomiting (4), Weight loss (3), Abnormal adrenocorticotropic hormone (ACTH) stimulation test (2), Not eating (2). Of the 10 reports with a coded outcome, Ongoing is the leading category at 50.0%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Tacrolimus Eye Drops.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial